Showing 1,523 results

Filters Content type: News, Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

New & experimental HIV treatments

Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1

Editor's pick
Bristol-Myers Squibb press release
15 April 2014
Activism & civil society

International Liver Conference: activists demand affordable hepatitis C treatment

Editor's pick
HepCoalition
11 April 2014
Pharmaceutical industry

U.S. drug industry group defends price of Gilead hepatitis drug

Editor's pick
Reuters
11 April 2014
Pharmaceutical industry

Gilead Sciences: How serious is the pricing problem?

Editor's pick
Barron's
9 April 2014
Access to healthcare

Gilead aims to license hepatitis C drug to 3-4 Indian firms

Editor's pick
Reuters
9 April 2014
Pharmaceutical industry

Express Scripts Raises Pressure on Gilead for Drug Price

Editor's pick
Bloomberg
8 April 2014
Access to healthcare

Global Fund And Tiered Medicines Pricing Under Debate

Editor's pick
Intellectual Property Watch
8 April 2014
Hepatitis C treatment

Costs to public of $84,000 hep C drug ‘outrageous' - Kaiser Permanente

Editor's pick
Reuters
3 April 2014
Drug-resistant TB

Big Pharma Abandons New Tuberculosis Drug Research

Editor's pick
CorpWatch.org
2 April 2014
Access to healthcare

Viiv Healthcare licenses dolutegravir (Tivicay) to Medicines Patent Pool

Editor's pick
Viiv Healthcare press release
2 April 2014
New & experimental HIV treatments

Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat as Part of Combination HIV Therapy

Editor's pick
Janssen press release
2 April 2014
Hepatitis C treatment

Push Comes To Shove: Gilead's $1,000 Pill Could Hurt Insurer Earnings

Editor's pick
Forbes
31 March 2014
The search for a cure

Gilead Following Multiple Paths Toward HIV “Functional Cure”

Editor's pick
Xconomy
25 March 2014
Pharmaceutical industry

US Lawmakers Attack Cost of New Hepatitis Drug

Editor's pick
New York Times
24 March 2014
HIV prevention policy

NY deal with drug maker paves way for plan to end HIV

Editor's pick
Albany Times Union
20 March 2014
Pharmaceutical industry

Merck HIV Drug Strategy Seen Shielding Patent: Corporate India

Editor's pick
Bloomberg
20 March 2014
Pharmaceutical industry

Trouble Ahead for Gilead and Sovaldi?

Editor's pick
Motley Fool
19 March 2014
Pharmaceutical industry

How Much Should Hepatitis C Treatment Cost?

Editor's pick
New York Times (editorial)
18 March 2014
Pharmaceutical industry

Can Gilead Dominate The HIV Drug Market Again in 2014?

Editor's pick
Motley Fool
13 March 2014
Pharmaceutical industry

AbbVie Does Not Appeal 9th Circuit Heightened Scrutiny Ruling

Editor's pick
Poz magazine news
12 March 2014
Access to healthcare

Global community-based networks unite to demand pharmaceuticals lower the price of hepatitis C treatment

Editor's pick
GNP+
10 March 2014
Access to healthcare

Pharma refuses to ensure access to lifesaving hepatitis C treatment at global meeting

Editor's pick
Treatment Action Group
28 February 2014
Access to healthcare

Fighting For Global Access to Hepatitis C Therapies

Editor's pick
HepMag
19 February 2014
Hepatitis C treatment

Treating HCV -- Is the Price Right?

Editor's pick
Med Page Today
19 February 2014